Sitryx
Created in 2018
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
3,970Activities
Technologies
Entity types
Location
Magdalen Centre, 1 Robert Robinson Ave, Littlemore, Oxford OX4 4GA, UK
Oxford
United Kingdom
Employees
Scale: 11-50
Estimated: 51
Engaged corporates
3
2 3Added in Motherbase
7 months ago
deeptech Value proposition
Harnessing the power of cell metabolism to develop groundbreaking disease-modifying therapies
Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation.
The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.
Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
Pioneers in immunometabolism - Sitryx
We’re altering immune cell metabolism to resolve disease. The field of immunometabolism is a rapidly emerging and exciting area of investigation into the role of intracellular metabolic pathways in immune cells.
https://www.sitryx.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Sofinnova Partners Financial Services | Sofinnova Partners Financial Services | Other 14 Apr 2024 | | |
 Oxford Science Enterprises Startup accelerator & VC, Venture Capital and Private Equity Principals | Oxford Science Enterprises Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 4 Jan 2024 | | |
 GSK Pharmaceutical, Pharmaceutical Manufacturing | GSK Pharmaceutical, Pharmaceutical Manufacturing | Other 26 Sep 2023 | | |